Arrowhead Pharmaceuticals
28 named things its latest annual report says its results depend on, each in the company's own words. 18 of them are also named by other companies we've read.
Suppliers
REDEMPLO single-source third-party manufacturer
depends onnamed as a riskFor instance, drug substance and drug product for REDEMPLO are each currently sourced from a single, third-party manufacturer, and many of our pulmonary product candidates are administered using a proprietary delivery device which is currently sourced from a single manufacturer.Risk factors (Item 1A)
Partners and platforms
Amgen Inc.
earns from · up to an additional $485.0 millionThe Company remains eligible to receive up to an additional $485.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma.Business (Item 1)
Takeda Pharmaceutical Company Limited
earns from · tiered royalties of 20% to 25% on net salesOutside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales.Business (Item 1)
Also named by NBIX
Vanscoy Rare Pharmacy
depends onnamed as a riskWe have an exclusive agreement with Vanscoy Rare Pharmacy for drug delivery services, and we expect to rely on this pharmacy for a considerable portion of our sales for REDEMPLO.Risk factors (Item 1A)
Sarepta Therapeutics, Inc.
earns fromnamed as a riskUnder our licensing and collaboration agreements with Amgen, Takeda, GSK, Sarepta, Visirna, Sanofi, and Novartis, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories.Risk factors (Item 1A)
Visirna
earns fromnamed as a riskThese geopolitical risks could also adversely affect Visirna.Risk factors (Item 1A)
Royalty Pharma
In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement.Business (Item 1)
Sanofi
earns from(1) Greater China rights for plozasiran are out-licensed to Sanofi.Business (Item 1)
GlaxoSmithKline (GSK)
earns fromOn December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the “GSK-HBV Agreement”) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company’s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection.Business (Item 1)
Alnylam Pharmaceuticals, Inc.
depends onUnder the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam’s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets.Business (Item 1)
Also named by REGN
Novartis Pharma AG
earns fromOn August 29, 2025, Novartis and the Company entered into a global licensing and collaboration agreement.Business (Item 1)
Other companies
Sixth Street Lending Partners
depends on · $500.0 millionnamed as a riskThe financing agreement establishes a senior secured term loan facility of $500.0 million (the “Credit Facility”), consisting of $400.0 million funded on the closing date and an additional $100.0 million available at our option, subject to mutual agreement with Sixth Street, over a seven-year term.Risk factors (Item 1A)
Competitors
Ionis Pharmaceuticals, Inc.
named as a riskFor example, as the Company previously reported in Form 8-K filed on September 12, 2025, Ionis Pharmaceuticals, Inc. (“Ionis”) filed a complaint for patent infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of United States Patent No. 9,593,333 (“the ’333 patent”) (the "Ionis Claim"), which may impact our planned commercialization of REDEMPLO.Risk factors (Item 1A)
Places
San Diego, California
operates in · more than 251,000 total square feetThe Company operates research laboratory facilities in San Diego, California and Madison, Wisconsin, where its pre-clinical research and development activities, including the discovery and early development of RNAi therapeutics, take place.Business (Item 1)
Verona, Wisconsin
operates in · approximately 300,000 total square feetDuring the first quarter of fiscal 2025, the Company further expanded into a new, state-of-the-art GMP manufacturing facility in Verona, Wisconsin that includes related laboratories and office space to support chemistry, manufacturing, and controls (CMC) and quality activities.Business (Item 1)
China
depends onnamed as a riskFor example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from mainland China, as well as other business restrictions.Risk factors (Item 1A)
Also named by A, AA, AAOI, AAP, AAPL, AB, ADI, AEHR and 261 more
Australia
operates innamed as a riskMost of our clinical trials involve study subjects outside of the United States, including most of our Phase 1 clinical trials (which often enroll study subjects in Australia and New Zealand), and our Phase 3 clinical trials of plozasiran and zodasiran, for which we have enrolled and plan to enroll cohorts outside the United States.Risk factors (Item 1A)
Also named by AJG, AXP, BF/B, BTU, CL, CSGP, CVX, DECK and 15 more
New Zealand
operates innamed as a riskMost of our clinical trials involve study subjects outside of the United States, including most of our Phase 1 clinical trials (which often enroll study subjects in Australia and New Zealand), and our Phase 3 clinical trials of plozasiran and zodasiran, for which we have enrolled and plan to enroll cohorts outside the United States.Risk factors (Item 1A)
Hazards
Russia-Ukraine conflict
named as a riskFor example, a number of our clinical trial sites we had previously planned to use in Russia, Ukraine, and Belarus were shut down and we had to seek alternatives in other geographies.Risk factors (Item 1A)
Also named by ABT, ADM, CAG, CDRE, DOW, EMN, FDX, FLR and 14 more
Commodities and inputs
Synthetic oligonucleotides
depends onnamed as a riskThere are a limited number of manufacturers that supply synthetic oligonucleotides.Risk factors (Item 1A)
Regulators
Laws and programs
U.S. pharmaceutical import tariffs
exposed to its price · up to 100% tariffsnamed as a riskFurthermore, in September 2025, the current Presidential Administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceutical products, subject to certain exceptions.Risk factors (Item 1A)
Medicare
earns fromnamed as a riskSales of REDEMPLO, or any other approved drug candidate, will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services.Risk factors (Item 1A)
Also named by ABT, AXGN, BAX, BDX, BMY, BSX, CAH, CDNA and 48 more
One Big Beautiful Bill Act
subject tonamed as a riskAnd the recently-enacted One Big Beautiful Bill Act (the “OBBBA”) imposes new restrictions on funding for government health care programs and on individual eligibility for coverage under those programs, which may lead to lower reimbursements for drugs covered by those programs.Risk factors (Item 1A)
Also named by AA, ABR, ADI, ADM, ALB, AMAT, AMGN, AMKR and 121 more
Medicaid
earns fromnamed as a riskSales of REDEMPLO, or any other approved drug candidate, will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services.Risk factors (Item 1A)
Also named by ABBV, ABT, ARE, BAX, BMY, BSX, CHE, CNC and 39 more
Inflation Reduction Act (IRA)
subject tonamed as a riskFor example, the IRA includes several measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with the Centers for Medicare & Medicaid Services ("CMS").Risk factors (Item 1A)
Also named by AEE, AMGN, BIIB, BKNG, BMY, CAH, CI, CNC and 26 more
Orphan Drug Act
subject tonamed as a riskIt is possible that another RNAi drug could be approved for the treatment of a disease that one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product’s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior.Risk factors (Item 1A)
Most Favored Nation drug pricing executive order
subject tonamed as a riskIn addition, an executive order issued by the White House on May 12, 2025, directs the Department of Health and Human Services (the “HHS”) to implement a “Most Favored Nation” drug pricing policy.Risk factors (Item 1A)